Overview
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors (TLRs), which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for our internal development programs and our partnered... More >> |  | |
|
| Date | Title | | | 09/08/10 | Idera Pharmaceuticals to Present at Upcoming Investor Conferences| CAMBRIDGE, Mass., Sep 08, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will provide an overview of its drug discovery and development programs targeted to Toll-like Receptors and a general corporate update at the following conferences:
The Rodman & Renshaw Annual Global Investment Conference on Wednesday, September 15 at 10:50 a.m. ET at the New York Palace Hotel, New York City
The UBS Global Life Sciences Conference on Monday, September 20 ... |
|  | | 08/27/10 | Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment| - Clinical Trial Initiated in First-Line Treatment of Patients with Head and Neck Cancer -
CAMBRIDGE, Mass., Aug 27, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combinatio... |
| | | 08/05/10 | Idera Pharmaceuticals Reports Second Quarter 2010 Financial Results and Provides Pipeline Update| CAMBRIDGE, Mass., Aug 05, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLRs), today reported financial results for the second quarter ended June 30, 2010.
"We are progressing the clinical development programs of IMO-2125, our lead candidate for chronic hepatitis C virus infection, and IMO-3100, our lead candidate for autoimmune and infla... |
| | | 08/02/10 | Idera Pharmaceuticals to Raise $15 Million in Registered Direct Offering| CAMBRIDGE, Mass., Aug 02, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals (Nasdaq: IDRA) today announced that it has received commitments from certain institutional investors to purchase approximately $15 million of securities in a registered direct offering. Idera expects to receive net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
In the offering Idera has agreed to sell approximately 4.0 million units, each unit consisting of one sha... |
| |
|
|
|
|
| Date | Title | | 09/15/10 10:50 a.m. ET | | | 09/20/10 7:30 a.m. ET | |
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
